» Articles » PMID: 6317018

Poly(ADP-ribose) Polymerase Inhibitors Preserve Nicotinamide Adenine Dinucleotide and Adenosine 5'-triphosphate Pools in DNA-damaged Cells: Mechanism of Stimulation of Unscheduled DNA Synthesis

Overview
Journal Biochemistry
Specialty Biochemistry
Date 1983 Oct 25
PMID 6317018
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Inhibitors of poly(ADP-ribose) polymerase stimulated the level of DNA, RNA, and protein synthesis in DNA-damaged L1210 cells but had negligible effects in undamaged L1210 cells. The poly(ADP-ribose) polymerase inhibitors stimulated DNA repair synthesis after cells were exposed to high concentrations of N-methyl-N'-nitro-N-nitrosoguanidine (68 and 136 microM) but not after exposure to low concentrations (13.6 and 34 microM). When the L1210 cells were exposed to 136 microM N-methyl-N'-nitro-N-nitrosoguanidine, the activation of poly(ADP-ribose) polymerase resulted in the rapid depletion of oxidized nicotinamide adenine dinucleotide (NAD+) levels and subsequent depletion of adenosine 5'-triphosphate (ATP) pools. After low doses of N-methyl-N'-nitro-N-nitrosoguanidine (13.6 microM), there were only small decreases in NAD+ and ATP. Poly(ADP-ribose) polymerase inhibitors prevented the rapid fall in NAD+ and ATP pools. This preservation of the ATP pool has a permissive effect on energy-dependent functions and accounts for the apparent stimulation of DNA, RNA, and protein synthesis. Thus, the mechanism by which poly(ADP-ribose) polymerase inhibitors stimulate DNA, RNA, and protein synthesis in DNA-damaged cells appears to be mediated by their ability to prevent the drastic depletion of NAD+ pools that occurs in heavily damaged cells, thereby preserving the cells' ability to generate ATP and maintain energy-dependent processes.

Citing Articles

Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment.

Chia M, Bulat F, Gaunt A, Ros S, Wright A, Sawle A Oncogene. 2024; 44(9):563-574.

PMID: 39639170 PMC: 11850285. DOI: 10.1038/s41388-024-03231-w.


Neuronal regulated cell death in aging-related neurodegenerative diseases: key pathways and therapeutic potentials.

Song R, Yin S, Wu J, Yan J Neural Regen Res. 2024; 20(8):2245-2263.

PMID: 39104166 PMC: 11759035. DOI: 10.4103/NRR.NRR-D-24-00025.


Efficacy of Clinically Used PARP Inhibitors in a Murine Model of Acute Lung Injury.

Martins V, Santos S, Rodrigues L, Salomao R, Liaudet L, Szabo C Cells. 2022; 11(23).

PMID: 36497049 PMC: 9738530. DOI: 10.3390/cells11233789.


Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy.

Saha S, Rundle S, Kotsopoulos I, Begbie J, Howarth R, Pappworth I Cancers (Basel). 2022; 14(17).

PMID: 36077823 PMC: 9454916. DOI: 10.3390/cancers14174288.


Poly(ADP-ribose) polymerase inhibition: past, present and future.

Curtin N, Szabo C Nat Rev Drug Discov. 2020; 19(10):711-736.

PMID: 32884152 DOI: 10.1038/s41573-020-0076-6.